Medina-Vera, D.; Rosell-Valle, C.; López-Gambero, A.J.; Navarro, J.A.; Zambrana-Infantes, E.N.; Rivera, P.; Santín, L.J.; Suarez, J.; Rodríguez de Fonseca, F.
Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity. Biology 2020, 9, 377.
https://doi.org/10.3390/biology9110377
AMA Style
Medina-Vera D, Rosell-Valle C, López-Gambero AJ, Navarro JA, Zambrana-Infantes EN, Rivera P, Santín LJ, Suarez J, Rodríguez de Fonseca F.
Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity. Biology. 2020; 9(11):377.
https://doi.org/10.3390/biology9110377
Chicago/Turabian Style
Medina-Vera, Dina, Cristina Rosell-Valle, Antonio J. López-Gambero, Juan A. Navarro, Emma N. Zambrana-Infantes, Patricia Rivera, Luis J. Santín, Juan Suarez, and Fernando Rodríguez de Fonseca.
2020. "Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity" Biology 9, no. 11: 377.
https://doi.org/10.3390/biology9110377
APA Style
Medina-Vera, D., Rosell-Valle, C., López-Gambero, A. J., Navarro, J. A., Zambrana-Infantes, E. N., Rivera, P., Santín, L. J., Suarez, J., & Rodríguez de Fonseca, F.
(2020). Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity. Biology, 9(11), 377.
https://doi.org/10.3390/biology9110377